TheraRadar
← Back
Data updated: Nov 8, 2026

RARE THYROID

Pharma
Pharmaceuticals

RARE THYROID is a pharmaceutical company with 1 FDA-approved products.

2026
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

RARE THYROID's Key Drugs

RARE THYROID's core commercial portfolio centers on EMCITATE — its most strategically important drugs approved in the last 15 years.

EMCITATE
Approved 2026

RARE THYROID's Recent FDA Approvals

RARE THYROID secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

EMCITATE NDA
2026-09-28
tiratricol

RARE THYROID's Therapeutic Areas

Disease areas where RARE THYROID has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

RARE THYROID Pipeline Snapshot

Active clinical trials for RARE THYROID across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • EMCITATE leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling